Jeffrey Anderson Douglas Zipes JEFFREY ANDERSON, University of Utah, Salt Lake City COMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis REFERENCE: Abstract 1020-89, American College of Cardiol
Jeffrey Anderson
Douglas Zipes
JEFFREY ANDERSON, University of Utah, Salt Lake CityCOMMENT: DOUGLAS ZIPES, University of Indiana, Indianapolis
REFERENCE: Abstract 1020-89, American College of Cardiology New OrleansThe hope of refining treatments for cardiovascular disease by genotyping patients to detect individual sensitivities to particular medical therapies was brought a step closer at the ACC meeting in New Orleans by results from a study using a rapid genothype test.Jeffrey Andersontold Peter Goodwin about the assay they’ve been investigating which indicates required dosing of warfarin.
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Bivalirudin For Angioplasty: Expensive Heparin?
Tony Gershlick Tony Gershlick, University of Leicester Adnan Kastrati, Deutsches Herzzentrum, Munich Using bivalirudin instead of heparin during angioplasty wasn’t any better for preventing deat
Remove Thrombus Before Primary Angioplasty!
Felix Zijlstra Felix Zijlstra, University Medical Center Groningen, The Netherlands Thrombus aspiration before percutaneous coronary intervention for acute myocardial infarction has multiple benefits,